ArticleInternational journal of pharmaceutics2026
Silk protein plastics for sustained and controlled drug release.
Article in International journal of pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in designing high-performance and enzymatically degradable plastics.Chemical science · 2026Review
- Silk-Based Protein Corona Enhances mRNA-LNP Vaccine Efficacy and Prevents Tumor Relapse.Advanced materials (Deerfield Beach, Fla.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recent advances in thermomechanical processing have enabled the solid-state molding of silk into dense, plastic-like biomaterials with tunable mechanical and degradation properties. In this study, we developed enzyme-embedded, drug-loaded silk reservoirs via thermoplastic molding and evaluated their in vitro drug release and degradation profiles. Reservoirs processed at varying temperatures (95 °C, 125 °C, 145 °C) exhibited temperature-dependent crystallinity, which directly influenced drug release rates and degradation timelines over a period of 70 days. Embedding proteolytic enzymes within the silk matrix provided an additional layer of control, enabling tunable sustained drug release. To demonstrate therapeutic relevance, we encapsulated doxorubicin, temozolomide, and L-asparaginase and evaluated their cytotoxicity against U87 glioblastoma cells. Encapsulated drugs retained bioactivity post-processing, outperforming thermally treated drugs without silk protection. These findings present, for the first time, that silk matrices stabilize both small-molecule and protein-based therapeutics under thermal stress. This work establishes a modular platform for long-acting drug delivery, combining structural tunability, enzymatic responsiveness, and thermal stability. The approach holds promise for localized treatment strategies in oncology and other applications requiring sustained release of labile compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.